Nautilus Biotechnology Q3 2026 revenue $0.2 million; net loss widens to $15.6 million
Nautilus Biotechnology reported third quarter 2026 results for the period ended September 30, 2026, with revenue of $0.2 million, mainly grant revenue, compared with no revenue a year earlier. Net loss widened to $15.6 million from $13.6 million as operating expenses rose 10% to $16.9 million, and cash, cash equivalents and investments stood at $114.3 million at quarter end.
Key points
- Q3 2026 revenue was $0.2 million, primarily grant revenue tied to a Michael J. Fox Foundation grant, versus no revenue in Q3 2025.
- Operating expenses rose $1.5 million, or 10%, to $16.9 million, driven by higher laboratory, professional services and salary costs.
- Net loss was $15.6 million, or $0.12 per share, compared with $13.6 million, or $0.11 per share, a year earlier.
- Cash, cash equivalents and investments were $114.3 million as of September 30, 2026; the company said it expects up to $6 million from the ARPA-H-funded SEEDS consortium.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.